Neuroendocrine Tumors clinical trials

Explore recruiting neuroendocrine tumors clinical trials.

Recruiting neuroendocrine tumors studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Neuroendocrine Tumors trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Neoplasms; Safety and Efficacy (RADNET)

Sweden

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Efficacy and safety of adjuvant peptide receptor radionuclide therapy after curative surgery of locoregional limited small intestine neuroendocrine neoplasia – a multi-center, prospective, open-label, two-arm parallel group, randomized, controlled, phase III study

Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2/3, multicenter, randomized open-label study of zanzalintinib vs everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors

France, Poland, Netherlands, Belgium, Germany, Spain +2 more

Phase II and Phase III (Integrated) EU CTIS Study details

Prognostic value of early assessment by ⁶⁸Ga-DOTATATE PET/CT for the treatment of well-differentiated grade 2 gastroenteropancreatic neuroendocrine tumors with ¹⁷⁷Lutetium-oxodotreotide.”

France

Therapeutic use (Phase IV) EU CTIS Study details

Randomized Interval Assessment trial of Lu177-Dotatate every 8 versus every 16 weeks in slowly progressive G1-2 advanced midgut neuroendocrine tumors (NETs) to Lower TOxicity.

Spain, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

First adjuvant trial in locally resected aggressive pancreatic neuroendocrine tumors: a randomized phase III investigating the efficacy of systemic chemotherapy (ADJUPANET)

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Neuroendocrine Tumors trials by city

Neuroendocrine Tumors in Toronto Neuroendocrine Tumors in Vancouver Neuroendocrine Tumors in Montreal Neuroendocrine Tumors in Calgary Neuroendocrine Tumors in Edmonton Neuroendocrine Tumors in Ottawa Neuroendocrine Tumors in Winnipeg Neuroendocrine Tumors in Quebec City Neuroendocrine Tumors in Hamilton Neuroendocrine Tumors in Kitchener Neuroendocrine Tumors in London Neuroendocrine Tumors in Halifax Neuroendocrine Tumors in New York Neuroendocrine Tumors in Los Angeles Neuroendocrine Tumors in Chicago Neuroendocrine Tumors in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease